 The Trial Innovation Network, TIN, was formed in response to the COVID-19 pandemic. It consisted of three Trial Innovation Centers, 16 Clinical and Translational Science Award Hub Institutions, and the Recruitment Innovation Center. The TIN adapted quickly to the rapidly changing landscape of the pandemic, providing 29 consults related to COVID-19 research between March 2020 and December 2020. These included six Trial Participation Expressions of Interest and eight Community Engagement Studios from the Recruitment Innovation Center. The TIN also experienced success with its remote research activities, data harmonisation and central safety reviews, and early community engagement and involvement. This article was authored by Rachel G. Greenberg, Laurie Poole, Daniel E. Ford and others.